{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:59:36Z","timestamp":1781247576016,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council, Taiwan","doi-asserted-by":"publisher","award":["113-2314-B-002-126-MY3"],"award-info":[{"award-number":["113-2314-B-002-126-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council, Taiwan","doi-asserted-by":"publisher","award":["114-2314-B-002-217-MY3"],"award-info":[{"award-number":["114-2314-B-002-217-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare, Taiwan","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-211-124001"],"award-info":[{"award-number":["MOHW114-TDU-B-211-124001"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["115-SS0026"],"award-info":[{"award-number":["115-SS0026"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["CTC115 MQ999"],"award-info":[{"award-number":["CTC115 MQ999"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["115-TMU112"],"award-info":[{"award-number":["115-TMU112"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Among patients with daptomycin-resistant and vancomycin-resistant Enterococcus faecium bloodstream infection (BSI), the optimal definitive therapy is uncertain. We estimated the dose effect of daptomycin (\u226511\u2005mg\/kg versus 8 to &amp;lt;11\u2005mg\/kg) on 28-day mortality and exploratorily described outcomes in patients treated with linezolid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with VRE BSI who received linezolid or daptomycin \u22658\u2005mg\/kg were included. Post hoc daptomycin MICs were determined by Sensititre broth microdilution (BMD), and episodes with MIC \u22658\u2005mg\/L were analyzed. The primary outcome was 28-day in-hospital mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 130 patients with daptomycin-resistant VRE BSI, 110 received daptomycin and 20 received linezolid. Within the daptomycin group, 28-day mortality was 55.1% (43\/78) with daptomycin 8 to &amp;lt;11\u2005mg\/kg and 34.4% (11\/32) with daptomycin \u226511\u2005mg\/kg. In adjusted analysis, daptomycin 8 to &amp;lt;11\u2005mg\/kg was associated with higher mortality than daptomycin \u226511\u2005mg\/kg [adjusted odds ratio (aOR) 3.11, 95% CI 1.13 to 8.56, P\u200a=\u200a0.03]. Among isolates with daptomycin MIC\u200a=\u200a8\u2005mg\/L, 28-day mortality was 54.9% in patients treated with daptomycin 8 to &amp;lt;11\u2005mg\/kg versus 29.6% treated with daptomycin \u226511\u2005mg\/kg (P\u200a=\u200a0.04); no benefit was seen for MIC \u226516\u2005mg\/L (P\u200a&amp;gt;\u200a0.99). 28-day mortality was 49.1% (54\/110) with daptomycin and 35.0% (7\/20) with linezolid (P\u200a=\u200a0.33); linezolid was not associated with lower mortality than daptomycin in adjusted analysis (P\u200a=\u200a0.48).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In daptomycin-resistant VRE BSI, daptomycin \u226511\u2005mg\/kg was associated with lower 28-day mortality than daptomycin 8 to &amp;lt;11\u2005mg\/kg, particularly at MIC\u200a=\u200a8\u2005mg\/L. Comparisons with the small linezolid arm are exploratory and underpowered. Larger studies are needed to confirm these hypothesis-generating findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag108","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:40:37Z","timestamp":1780141237000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes of daptomycin- and vancomycin-resistant\n                    <i>Enterococcus faecium<\/i>\n                    bloodstream infection"],"prefix":"10.1093","volume":"8","author":[{"given":"Wei-Ting","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch , Yun-Lin County 640203 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hsi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch , Hsin-Chu City 300195 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-9010","authenticated-orcid":false,"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-4139","authenticated-orcid":false,"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital , 7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100225 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026061202172693600_dlag108-B1","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/jcpt.13383","article-title":"Prevalence of vancomycin-resistant Enterococci in Asia-A systematic review and meta-analysis","volume":"46","author":"Shrestha","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"2026061202172693600_dlag108-B2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026061202172693600_dlag108-B4","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00058\u201318","article-title":"The Enterococcus: a model of adaptability to its environment","volume":"32","author":"Garc\u00eda-Solache","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2026061202172693600_dlag108-B5","author":"CLSI","year":"2025"},{"key":"2026061202172693600_dlag108-B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: a pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2026061202172693600_dlag108-B7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1517\/14656560902811811","article-title":"Therapeutic options for infections due to vancomycin-resistant Enterococci","volume":"10","author":"Wang","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2026061202172693600_dlag108-B8","doi-asserted-by":"publisher","first-page":"890.e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2026061202172693600_dlag108-B9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026061202172693600_dlag108-B10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B11","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jac\/dkaf055","article-title":"Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant Enterococci: a multicentre clinical experience","volume":"80","author":"Serapide","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026061202172693600_dlag108-B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02216-16","article-title":"Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant Enterococcus faecium bacteremia","volume":"61","author":"Britt","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, Medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B14","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/cid\/ciab001","article-title":"Emergence and transmission of daptomycin and vancomycin-resistant Enterococci between patients and hospital rooms","volume":"73","author":"Haddad L","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/cid\/ciq113","article-title":"Daptomycin nonsusceptible Enterococci: an emerging challenge for clinicians","volume":"52","author":"Kelesidis","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/antibiotics11040427","article-title":"Antimicrobial susceptibility testing: a comprehensive review of currently used methods","volume":"11","author":"Gajic","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026061202172693600_dlag108-B17","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/cid\/ciz845","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other Enterococcal species by the Clinical and Laboratory Standards Institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2026061202172693600_dlag108-B19","author":"US Food and Drug Administration"},{"key":"2026061202172693600_dlag108-B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113710","article-title":"Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant Enterococcus bloodstream infection","volume":"155","author":"Chuang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026061202172693600_dlag108-B21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/cid\/ciq154","article-title":"Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia","volume":"52","author":"Chuang","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkac164","article-title":"Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin","volume":"77","author":"Chuang","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026061202172693600_dlag108-B23","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/jac\/dkac042","article-title":"Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm)","volume":"77","author":"Kelly","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026061202172693600_dlag108-B24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026061202172693600_dlag108-B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"2026061202172693600_dlag108-B27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2026061202172693600_dlag108-B28","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.clinthera.2016.09.011","article-title":"Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4 mg\/L","volume":"38","author":"Chong","year":"2016","journal-title":"Clin Ther"},{"key":"2026061202172693600_dlag108-B29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00745\u201318","article-title":"Variability of daptomycin MIC values for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests","volume":"62","author":"Campeau","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B30","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1128\/JCM.03439-13","article-title":"Systematic evaluation of commercial susceptibility testing methods for determining the in vitro activity of daptomycin versus Staphylococcus aureus and Enterococci","volume":"52","author":"Kirn","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2026061202172693600_dlag108-B31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1469-0691.1999.tb00434.x","article-title":"MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type Enterococci obtained from intensive care unit patient surveillance cultures","volume":"5","author":"Cant\u00f3n","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"2026061202172693600_dlag108-B32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026061202172693600_dlag108-B33","author":"US Food and Drug Administration"},{"key":"2026061202172693600_dlag108-B34","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01069-23","article-title":"Liax is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium","volume":"68","author":"Axell-House","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jmii.2025.08.005","article-title":"High-dose daptomycin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bloodstream infections: role of pharmacodynamic target attainment","volume":"59","author":"Hwang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"2026061202172693600_dlag108-B36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B37","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of Enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026061202172693600_dlag108-B38","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1128\/AAC.00526-13","article-title":"Multicenter study of high-dose daptomycin for treatment of enterococcal infections","volume":"57","author":"Casapao","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061202172693600_dlag108-B39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01317-20","article-title":"Daptomycin resistance in Enterococcus faecium can be delayed by disruption of the LiaFSR stress response pathway","volume":"65","author":"Prater","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag108\/68515894\/dlag108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag108\/68515894\/dlag108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:17:34Z","timestamp":1781245054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag108\/8706715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag108","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"dlag108"}}